This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabbatini, P. Articles by Odunsi, K. Search for Related Content PubMed PubMed Citation Articles by Sabbatini, P. Articles by Odunsi, K.

Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Authors' Affiliations: ¹ Memorial Sloan-Kettering Cancer Center, New York, New York; ² Franklin Square Hospital, Baltimore, Maryland; ³ University of Marburg, Marburg, Germany; and ⁴ Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Kunle Odunsi, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-3497; Fax: 716-845-7608; E-mail: Kunle.odunsi{at}roswellpark.org.

Purpose: This open-label study assessed the safety and immunogenicity of two doses and two routes of the anti-idiotypic monoclonal antibody abagovomab (formerly ACA125) in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Experimental Design: Eligible patients from the three participating institutions were any stage at diagnosis, had relapsed, and had complete or partial response to additional chemotherapy. Patients were randomized to receive abagovomab at 2.0 versus 0.2 mg and i.m. versus s.c. for four immunizations every 2 weeks and then monthly for two additional immunizations. Planned evaluation included interval physical examinations and laboratory assessments with immune assessment, including HLA typing, human anti-mouse antibody, ELISA, and enzyme-linked immunospot. Patients were required to remain on study until week 10 (the first post-baseline Ab3 determination) to be considered for immunologic assessment. The primary end points were safety and immunogenicity primarily determined by Ab3 response.

Results: Forty-two patients received at least one vaccination and were eligible for safety analysis. Thirty-three patients were available for Ab3 analysis (removed for progression of disease, 6; withdrawal of consent, 2; unrelated adverse event, 1). The most common adverse events were self-limited pain at injection site, myalgia, and fever. No hematologic or nonhematologic toxicity grade >2 related to immunization was seen. Ab3 was detectable in all patients (median, 236,794 ng/mL); none of route of administration (P = 0.6268), dose (P = 0.4602), or cohort (P = 0.4944) was statistically significant in terms of effect on maximum post-baseline Ab3 titer. Human anti-mouse antibody was not detectable at baseline but was present in all patients at week 16 (range, 488-45,000 ng/mL).

Conclusions: Immunization with abagovomab is well tolerated and induced robust Ab3 responses at the two doses and routes tested. A phase III randomized study with abagovomab (2.0 mg s.c.) is warranted.

This article has been cited by other articles:

				C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748. [Abstract] [Full Text] [PDF]

				B. C. Schultes, L. M. Smith, and C. F. Nicodemus Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Clin. Cancer Res., July 1, 2007; 13(13): 4026 - 4026. [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Reply to the Letter to the Editor from Schultes et al Clin. Cancer Res., July 1, 2007; 13(13): 4026 - 4026. [Full Text] [PDF]

				Y. Chen, S. Clark, T. Wong, Y. Chen, Y. Chen, M. S. Dennis, E. Luis, F. Zhong, S. Bheddah, H. Koeppen, et al. Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models Cancer Res., May 15, 2007; 67(10): 4924 - 4932. [Abstract] [Full Text] [PDF]